Procedural Sedation Clinical Trial
Official title:
Propofol-Ketamine (Ketofol) Versus Propofol-Fentanyl (Fenofol) as Procedural Sedation for Unilateral Open Carpal Tunnel Release Under Local Anesthesia
There are different methods of anesthesia for CTR surgery. Procedural sedation will allow rapid recovery and fewer complications than regional or general anesthesia (GA). Attempts have been made in the past to use additives with propofol to reduce its dose. Ketofol (ketamine/propofol combination) was used for procedural sedation and analgesia. Ketamine and propofol administered in combination have offered effective sedation for spinal anesthesia and for gynecologic, ophthalmologic, and cardiovascular procedures in all age groups. The opposing hemodynamic and respiratory effects of each drug may enhance the utility of this drug combination, increasing both safety and efficacy and allowing reduction in the dose of propofol required to achieve sedation. Propofol alone had a significantly greater number of apnea with desaturation (SpO2 < 90%) episodes. Further, it has been shown that during colonoscopies, propofol in combination with fentanyl provided similar patient satisfaction with shorter recovery times even at lower depths of sedation as compared to propofol. The addition of fentanyl to propofol has been shown to result in better operator feasibility with no difference in recovery time, cognitive impairment, or complications as compared to the use of propofol only for sedation.
Status | Recruiting |
Enrollment | 56 |
Est. completion date | May 1, 2021 |
Est. primary completion date | April 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 55 Years |
Eligibility | Inclusion Criteria: - Age: 21-55 years old. - Sex: both sex (males or females). - Physical status: ASA I & II. - BMI: 25-30 kg/m2. - Type of operation: elective unilateral CTR under local anesthesia. - Written informed consent from the patient. - Cooperative patient. Exclusion Criteria: - Patient refusal. - Altered mental status. - Patients with known history of allergy to study drugs. - Severe hepatic, renal, Cardiovascular and respiratory diseases. - Patients on regular sedative or pain killer medications. |
Country | Name | City | State |
---|---|---|---|
Egypt | Zagazig University | Zagazig |
Lead Sponsor | Collaborator |
---|---|
Zagazig University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | depth of sedation | assessed by Modified Ramsay sedation scale. Score Modified Ramsay Sedation Scale Score
Awake and alert, minimal or no cognitive impairment Awake but tranquil, purposeful responses to verbal commands at conversational level Appears asleep, purposeful responses to verbal commands at conversational level Appears asleep, purposeful responses to verbal commands but at louder than usual conversational level, requiring light glabellar tap, or both Asleep, sluggish purposeful responses only to loud verbal commands, strong glabellar tap, or both Asleep, sluggish purposeful responses only to painful Stimuli Asleep, reflex withdrawal to painful stimuli only (no purposeful responses) Unresponsive to external stimuli, including pain interpretation: score 1= minimal sedation score 2-4=moderate sedation score 5-7=deep sedation score 8=anesthesia |
from drug injection up to 15 minutes till modified Ramsay sedation scale = 4 | |
Secondary | recovery time | The time from discontinuation of infusion drug to first response to verbal command | up to 30 minutes postoperative | |
Secondary | • The total duration of post-anesthesia care unit (PACU) stay (The time from arrival to the PACU to discharge to the ward) according to modified Aldrete score 9 | Modified Aldert score. Assessment items Condition Grade Activity, able to move, voluntarily or on command 4 extremities 2 2 extremities 1 No 0
Breathing Able to breathe deeply & cough freely 2 Dyspnea, shallow or limited breathing 1 Apnea 0 Consciousness Fully awake 2 Arousable on calling 1 Unresponsive 0 Circulation (BP) ±20% of pre-anesthesia level 2 20% to 49% of pre-anesthesia level 1 50% of pre-anesthesia level 0 SPO2 Maintains SpO2 >92% in ambient air 2 Maintain SpO2 >90% with O2 1 Maintain SpO2 <90% with O2 0 • Patient having a score of 9 or higher is discharged |
up to 1 hour postoperative | |
Secondary | Total propofol consumption by mg | intraoperatice total propofol consumption by mg | from the start of drug injection till discontinuation of propfol infusion about 1 hour | |
Secondary | number of participants with intraoperative complications such as hypotenstion, bradycardia and hypoxia | Intraoperative Complications such as hypotension (a decrease in mean arterial pressure 20% from base line mean arterial pressure, it will be treated with intravenous fluids and incremental doses of ephedrine), bradycardia (a decrease in heart rate 20% from base line heart rate, it will be treated with atropine) and hypoxia (a decrease in O2 saturation below 92%) will be treated with increasing O2 flow | from the start of drug injection till end of surgery about 1 hour | |
Secondary | number of participants with postoperative complications such as postoperative nausea and vomting | number of participants with postoperative complications such as postoperative nausea and vomting | within 12 hours postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03692390 -
Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department
|
N/A | |
Completed |
NCT02145169 -
Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study
|
N/A | |
Recruiting |
NCT05595798 -
EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
|
||
Completed |
NCT01260662 -
Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation
|
Phase 4 | |
Completed |
NCT00784498 -
Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department
|
Phase 4 | |
Completed |
NCT00327392 -
A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.
|
Phase 2/Phase 3 | |
Recruiting |
NCT04873596 -
Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03329014 -
A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability
|
Phase 1 | |
Recruiting |
NCT06414395 -
The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study
|
Phase 4 | |
Recruiting |
NCT03860831 -
Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities:
|
Phase 1 | |
Completed |
NCT00869440 -
Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy
|
Phase 2 | |
Not yet recruiting |
NCT05757622 -
Electroencephalogram Based Real-Time Sedation Level Prediction
|
||
Completed |
NCT03799783 -
The Use of Dexmedetomidine for EEG Sedation in Children With Behavioural Disorders
|
Phase 2 | |
Completed |
NCT02180737 -
Dexmedetomidine for Sedation During Radiological Interventional Procedures
|
Phase 4 | |
Not yet recruiting |
NCT01227174 -
Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery
|
Phase 4 | |
Recruiting |
NCT03499886 -
Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique
|
Phase 2/Phase 3 | |
Completed |
NCT03747432 -
Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation
|
Phase 4 | |
Recruiting |
NCT06203522 -
Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
|
||
Withdrawn |
NCT05783492 -
INK Feasibility Study
|
Phase 3 | |
Completed |
NCT02955732 -
Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients
|
Phase 4 |